Acute ischemic stroke in the pediatric population is rare but carries lasting and often lifelong morbidity. Thrombolysis and mechanical thrombectomy are mainstays of care in adults, yet there is very little evidence for these treatments in children. We present the case of a 4-year-old boy with complex congenital heart disease, admitted 30 min after sudden onset of an aphasia and right hemiplegia, scoring 14 on the Pediatric National Institutes of Health Stroke Scale (PedNIHSS). Non-contrast brain computed tomography (CT) showed no evidence of acute ischemia. CT angiogram demonstrated a thrombus in the M1 segment of the left middle cerebral artery. Intravenous recombinant tissue plasminogen activator (rTPA) was infused 3.5 h after onset of symptoms. An improvement was observed in the hour after rTPA, with a PedNIHSS score of 7. Digital subtraction angiography was performed approximately 9 h from the onset of symptoms, showing a complete left M1 occlusion. The patient underwent successful mechanical thrombectomy and was discharged with a PedNIHSS score of 2. This case emphasizes the importance of early recognition to direct children towards rapid diagnosis and hyperacute treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739694PMC
http://dx.doi.org/10.1159/000496535DOI Listing

Publication Analysis

Top Keywords

mechanical thrombectomy
12
acute ischemic
8
ischemic stroke
8
onset symptoms
8
pednihss score
8
stroke child
4
child treated
4
treated thrombolytic
4
thrombolytic therapy
4
therapy mechanical
4

Similar Publications

Objectives: Blood pressure (BP) management is challenging in patients with acute ischemic supratentorial stroke undergoing recanalization therapy due to the lack of established guidelines. Assessing dynamic cerebral autoregulation (dCA) may address this need, as it is a bedside technique that evaluates the transfer function phase in the very low-frequency (VLF) range (0.02-0.

View Article and Find Full Text PDF

Outcomes and Complications Associated with Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke.

Cardiol Cardiovasc Med

December 2024

Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona CA 91766, USA.

Universally, stroke presents as neurological deficits due to the obstruction of blood supply to specific regions of the brain. Among the three main categories of stroke, acute ischemic stroke is the leading cause of death and disability worldwide. As of today, there are two effective treatment methods: thrombolysis and endovascular therapy.

View Article and Find Full Text PDF

Disseminated venous thromboembolism (VTE) occurs commonly in cancer patients, who tend to have contraindications to systemic thrombolysis and require cancer surgery. Such clinical scenarios are often challenging to manage. In this case report, we illustrate an innovative, single procedural approach in such a patient to remove extensive VTE, improve symptoms, prevent hemodynamic decompensation, and allow for a minimal level of anticoagulation such that necessary cancer surgery can proceed safely.

View Article and Find Full Text PDF

We report a case in which mechanical thrombectomy (MT) was performed on a patient with cerebral infarction and renal failure, and contrast leakage remained on postoperative head computed tomography (CT) scans for more than 24 hours. A 75-year-old woman with a medical history of chronic renal failure due to diabetic nephropathy was admitted to the cardiology department of our hospital with chronic heart failure. During hospitalization, her diabetic nephropathy worsened.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the cost-effectiveness of using mechanical thrombectomy (MT) alongside standard medical care (SMC) for patients aged 90 and older suffering from acute ischemic stroke (AIS).
  • A simulation model estimated that MT with SMC provided 1.463 quality-adjusted life years (QALYs) at a cost of 14,553,772 Yen, compared to 1.054 QALYs for SMC alone, which cost 13,732,646 Yen.
  • The findings suggest that the incremental cost-effectiveness ratio (ICER) of MT with SMC is 2,009,744 Yen per QALY, indicating a 66% chance that this approach
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!